Concepts (109)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Rib Fractures | 1 | 2015 | 38 | 0.500 |
Why?
|
Cartilage | 1 | 2015 | 110 | 0.490 |
Why?
|
Pseudomonas Infections | 2 | 2016 | 166 | 0.480 |
Why?
|
Fracture Fixation, Internal | 1 | 2015 | 97 | 0.480 |
Why?
|
Thoracic Wall | 1 | 2015 | 188 | 0.430 |
Why?
|
Thoracic Surgical Procedures | 1 | 2015 | 259 | 0.380 |
Why?
|
Pseudomonas aeruginosa | 2 | 2016 | 252 | 0.380 |
Why?
|
Pneumonia, Bacterial | 1 | 2012 | 135 | 0.370 |
Why?
|
Toll-Like Receptor 4 | 1 | 2012 | 210 | 0.360 |
Why?
|
Lung Injury | 1 | 2012 | 145 | 0.360 |
Why?
|
Heart-Assist Devices | 7 | 2009 | 1042 | 0.320 |
Why?
|
Dextrocardia | 1 | 2005 | 11 | 0.250 |
Why?
|
Heart Failure | 5 | 2009 | 2330 | 0.210 |
Why?
|
Wounds and Injuries | 2 | 2015 | 437 | 0.190 |
Why?
|
Multiple Trauma | 1 | 2016 | 77 | 0.130 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2015 | 142 | 0.110 |
Why?
|
Multiple Organ Failure | 1 | 2015 | 177 | 0.110 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 243 | 0.110 |
Why?
|
Heart Transplantation | 4 | 2007 | 897 | 0.100 |
Why?
|
Hypersensitivity, Delayed | 1 | 2012 | 107 | 0.100 |
Why?
|
Toll-Like Receptor 2 | 1 | 2012 | 95 | 0.100 |
Why?
|
Mice, Inbred Strains | 1 | 2012 | 563 | 0.100 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 2012 | 269 | 0.100 |
Why?
|
Monocytes | 1 | 2015 | 790 | 0.090 |
Why?
|
Pneumonia | 1 | 2016 | 796 | 0.090 |
Why?
|
Flow Cytometry | 2 | 2015 | 3045 | 0.080 |
Why?
|
Disease Susceptibility | 1 | 2012 | 550 | 0.080 |
Why?
|
Myocardium | 2 | 2005 | 1232 | 0.080 |
Why?
|
Endomyocardial Fibrosis | 1 | 2006 | 5 | 0.070 |
Why?
|
Early Ambulation | 1 | 2006 | 23 | 0.070 |
Why?
|
Up-Regulation | 1 | 2012 | 2422 | 0.070 |
Why?
|
Proteoglycans | 1 | 2006 | 279 | 0.060 |
Why?
|
Ventricular Remodeling | 1 | 2006 | 188 | 0.060 |
Why?
|
Extracellular Matrix Proteins | 1 | 2006 | 293 | 0.060 |
Why?
|
Equipment Failure | 1 | 2005 | 191 | 0.060 |
Why?
|
Hypertension, Pulmonary | 1 | 2009 | 464 | 0.060 |
Why?
|
Antibody Formation | 1 | 2005 | 386 | 0.060 |
Why?
|
Brain Death | 1 | 2005 | 59 | 0.060 |
Why?
|
Heart Ventricles | 2 | 2006 | 847 | 0.060 |
Why?
|
Cardiac Output, Low | 1 | 2004 | 76 | 0.060 |
Why?
|
Male | 10 | 2016 | 128315 | 0.050 |
Why?
|
Ventricular Function | 1 | 2003 | 100 | 0.050 |
Why?
|
Obesity | 1 | 2015 | 2904 | 0.050 |
Why?
|
Mast Cells | 1 | 2004 | 229 | 0.050 |
Why?
|
T-Lymphocytes | 1 | 2015 | 3949 | 0.050 |
Why?
|
Respiration, Artificial | 1 | 2006 | 585 | 0.050 |
Why?
|
Fibroblasts | 2 | 2006 | 1654 | 0.050 |
Why?
|
Cell Communication | 1 | 2004 | 512 | 0.050 |
Why?
|
Transforming Growth Factor beta | 1 | 2006 | 1109 | 0.050 |
Why?
|
Graft Rejection | 1 | 2005 | 847 | 0.050 |
Why?
|
Myocardial Ischemia | 1 | 2003 | 421 | 0.040 |
Why?
|
Middle Aged | 7 | 2015 | 90352 | 0.040 |
Why?
|
Coronary Artery Bypass | 1 | 2003 | 530 | 0.040 |
Why?
|
Treatment Outcome | 4 | 2015 | 33737 | 0.040 |
Why?
|
Comorbidity | 1 | 2005 | 2394 | 0.040 |
Why?
|
Liver Transplantation | 1 | 2007 | 1195 | 0.040 |
Why?
|
Interleukin-6 | 2 | 2016 | 1050 | 0.030 |
Why?
|
Aged | 5 | 2015 | 73333 | 0.030 |
Why?
|
Kidney | 1 | 2005 | 2121 | 0.030 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2016 | 1584 | 0.030 |
Why?
|
Cytokines | 1 | 2005 | 2825 | 0.030 |
Why?
|
Mice | 2 | 2016 | 35600 | 0.030 |
Why?
|
Injury Severity Score | 1 | 2015 | 246 | 0.030 |
Why?
|
Patient Outcome Assessment | 1 | 2015 | 245 | 0.030 |
Why?
|
Humans | 11 | 2015 | 270740 | 0.030 |
Why?
|
Lung | 1 | 2005 | 3298 | 0.030 |
Why?
|
Interleukin-10 | 1 | 2016 | 483 | 0.030 |
Why?
|
Animals | 3 | 2016 | 61956 | 0.030 |
Why?
|
Cells, Cultured | 2 | 2006 | 5694 | 0.020 |
Why?
|
Decorin | 1 | 2006 | 12 | 0.020 |
Why?
|
Retrospective Studies | 4 | 2015 | 39890 | 0.020 |
Why?
|
Polyethylene Terephthalates | 1 | 2005 | 44 | 0.020 |
Why?
|
RNA, Messenger | 2 | 2006 | 6390 | 0.020 |
Why?
|
Physical Therapy Modalities | 1 | 2006 | 92 | 0.020 |
Why?
|
Hemodynamics | 1 | 2009 | 949 | 0.020 |
Why?
|
Adolescent | 3 | 2015 | 32767 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2016 | 7100 | 0.020 |
Why?
|
Survival Analysis | 2 | 2007 | 9292 | 0.020 |
Why?
|
Receptors, Interleukin-6 | 1 | 2005 | 65 | 0.010 |
Why?
|
HSP47 Heat-Shock Proteins | 1 | 2004 | 5 | 0.010 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2005 | 227 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2006 | 768 | 0.010 |
Why?
|
Collagen | 1 | 2006 | 727 | 0.010 |
Why?
|
Interleukin-1 | 1 | 2005 | 475 | 0.010 |
Why?
|
Adult | 4 | 2015 | 82040 | 0.010 |
Why?
|
Organ Specificity | 1 | 2005 | 737 | 0.010 |
Why?
|
Female | 6 | 2015 | 148940 | 0.010 |
Why?
|
Coculture Techniques | 1 | 2004 | 628 | 0.010 |
Why?
|
Heat-Shock Proteins | 1 | 2004 | 327 | 0.010 |
Why?
|
Cell Separation | 1 | 2004 | 609 | 0.010 |
Why?
|
Recovery of Function | 1 | 2006 | 681 | 0.010 |
Why?
|
Equipment Design | 1 | 2005 | 1197 | 0.010 |
Why?
|
Survivors | 1 | 2007 | 1021 | 0.010 |
Why?
|
Hemorrhage | 1 | 2005 | 727 | 0.010 |
Why?
|
Risk Factors | 2 | 2009 | 17888 | 0.010 |
Why?
|
Ventricular Function, Left | 1 | 2004 | 564 | 0.010 |
Why?
|
Swine | 1 | 2005 | 1607 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2006 | 3476 | 0.010 |
Why?
|
Critical Illness | 1 | 2006 | 739 | 0.010 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2003 | 400 | 0.010 |
Why?
|
Registries | 1 | 2005 | 2211 | 0.010 |
Why?
|
Young Adult | 1 | 2015 | 22251 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2006 | 4130 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2015 | 30998 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2005 | 5149 | 0.010 |
Why?
|
Time Factors | 1 | 2006 | 13006 | 0.010 |
Why?
|
Child, Preschool | 1 | 2007 | 17061 | 0.010 |
Why?
|
United States | 1 | 2003 | 15861 | 0.000 |
Why?
|
Child | 1 | 2007 | 30559 | 0.000 |
Why?
|